Gastric electrical stimulation (GES), also referred to as gastric pacing is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastro paresis of diabetic, idiopathic, or post-surgical ethology. Gastric electrical stimulation has also been investigated as a treatment of obesity too. The device may be referred to as a gastric pacemaker. Gastric electrical stimulation has been investigated as a treatment of obesity as a technique to increase a feeling of satiety with subsequent reduced food intake and weight loss. The exact mechanisms resulting in changes in eating behaviour are uncertain but may be related to neuron-hormonal modulation and/or stomach muscle stimulation. Gastric electrical stimulation ameliorated symptoms, returned patients to normal oral nutritional intake, increased body mass index, improved gastric emptying rates, and is an alternative to gastrostomy in patients with end-stage gastric disease.
Covid-19 Scenario analysis:
COVID-19 on surgeries, has projected that, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide will cancelled or postponed in 2020, the researchers said. With Corona Virus Disease 2019 (COVID-19), the world is fighting a health pandemic as well as an economic pandemic, almost impacting trillions of dollars of revenues. More than 28 million planned surgeries across the world could be cancelled as a result of the COVID-19 pandemic, leading to patients facing a lengthy wait for their health issues to be resolved, according to a study. During the COVID-19 pandemic, elective surgeries have been cancelled to reduce the risk of patients being exposed to COVID-19 in hospital, and to support the wider hospital response, for example by converting operating theatres in to intensive care units. The researchers’ project that worldwide 72.3% planned surgeries would be cancelled through the peak period of COVID-19 related disruption, adding that most cancelled surgeries will be for non-cancer conditions, which includes the Gastric electric stimulation; thereby impacting the market growth.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:
Drivers:
Rise in Gastroparesis disease:
Gastroparesis is a disease in which the stomach cannot empty itself of food in a normal fashion. This is a common condition in people who have had diabetes for a long time, but it may also occur in other situations. Gastroparesis is caused by nerve injury, including damage to the valgus nerve. In its normal state, the valgus nerve contracts (tightens) the stomach muscles to help move food through the digestive tract. In cases of Gastroparesis, the valgus nerve is damaged by diabetes. This prevents the muscles of the stomach and intestine from working properly, which keeps food from moving from the stomach to the intestines. Rise in prevalence of delayed gastric emptying, also known as Gastroparesis, is a major driver of the global gastric electrical stimulators market. Gastroparesis is a gastric motor disorder which leads to chronic nausea and vomiting and results in frequent hospital admissions and poor quality of life of patients. Gastroparesis is often associated with diabetes and can occur along with gastrointestinal disorders such as gastric ulcer, achalasia, atrophic gastritis, and celiac disease. This is projected to fuel demand for gastric electrical stimulators in the near future.
High-Frequency Gastric Electric Stimulators Gain Popularity:
According to the report, high-frequency gastric electric stimulators is gaining immense traction as one of the highly effective product type, versus low-frequency gastric electric stimulators. Apart from being less invasive and more patient-friendly in terms of insertion, high-frequency gastric electric stimulators are known to have a relatively longer battery life compared to low-frequency gastric electric stimulators. In addition, gastric electrical stimulation with high-frequency significantly improved the severity of nausea and vomiting combined with enhanced propagation velocity and slow wave amplitude.
Only method to cure Gastroparesis:
Gastroparesis is a rare condition which cannot be managed with traditional medication treatment options. Gastric electrical stimulation is the only therapy option which can help in managing the Gastroparesis. Gastric electrical stimulators market is expected to grow over the forecast period due to above mentioned factor. The other factor driving the growth of gastric electrical stimulators market is increasing prevalence of both type 1 and type 2 diabetes, as they are the primary cause of Gastroparesis.
Restrains:
Complications associated with GES including infection, bleeding, bruising, implant site pain, gastric perforation, lead penetration, bowel obstruction or perforation, irritation/inflammation over implant site, lead entanglement or erosion, and device mechanical or electrical problem are expected to restrain the global market
Currently, no GES devices has been approved by FDA for the treatment of obesity. The Transcend® (Transneuronix; acquired by Medtronic in 2005), an implantable gastric stimulation device, is available in Europe for treatment of obesity.
Regional analysis:
North America is has the largest share in the global market. Rise in the number of gastrointestinal surgical procedures performed in the U.S., high prevalence of Gastroparesis, and favourable regulatory and reimbursement policies for GES are anticipated augment the market in the country. Rise in prevalence of obesity and diabetic Gastroparesis in countries in Europe is expected to propel demand for GES in the country. Large patient pool and rapid adoption of western lifestyle leading to increased risk of chronic disorders such as obesity, diabetes, and gastrointestinal disorders in the developing countries including India and China, are the key factors expected to augment the gastric electrical stimulators market in Asia Pacific.
Key benefits of the report:
- This study presents the analytical depiction of the global Gastric electric stimulators industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Gastric electric stimulators market share.
- The current market is quantitatively analyzed to highlight the global Gastric electric stimulators market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Gastric electric stimulators market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Gastric electric stimulators Market research report:
- What are the leading market players active in the Gastric electric stimulators market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Gastric Electric Stimulators Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | EnteroMedics, Medtronic Plc., MetaCure, ReShape Lifesciences, Inc., Ltd, Philipis, Stryker Corporation, ANS, Changzhou Ruishen Medical Equipment Co, IntraPace Inc. |
 Other Players | GE Healthcare |
Loading Table Of Content...
